2 research outputs found
Comparative potency of formulations of mometasone furoate in terms of inhibition of 'PIRHR' in the forearm skin of normal human subjects measured with laser doppler velocimetry
BACKGROUND AND AIMS: Topical glucocorticoid formulations are widely
used for effective treatment and control of a variety of dermatoses.
Mometasone furoate is a newer corticoid that has high potency but low
systemic toxicity. Pharmaceutical factors are known to significantly
influence potency and systemic absorption of topically applied
glucocorticoids. We studied the potency of "Elocon", a topical
formulation of mometasone furoate, compared with two other branded
formulations of the same corticoid. METHODS: Corticoid potency was
measured by employing a pharmacodynamic parameter of an inhibitory
effect of the corticoid on post-ischemic-reactive-hyperemic-response
(PIRHR) in human forearm skin under occlusive dressing. The PIRHR was
expressed in terms of % increase in the skin blood flow (SBF) as
measured with laser doppler velocimetry (LDV). RESULTS : All three
active branded formulations of mometasone furoate produced significant
inhibition of PIRHR. The AUC (0-2min) of PIRHR was ( Mean ± SEM ),
Control = 213.52 ± 11.80, Placebo = 209.77 ± 19.31,
Formulation A = 119.83 ± 13.71, Formulation C = 53.67 ± 4.85
and Formulation D = 111.46 ± 22.87. Formulation "C" exhibited
significantly higher topical anti-inflammatory potency than
formulations "A" or "D". CONCLUSIONS: Thus, branded formulations of the
same glucocorticoid, mometasone furoate significantly differed in their
topical anti-inflammatory potency. "Elocon" was significantly more
potent than the two other branded formulations studied
Diagnosis and Management of Hypothyroidism: Addressing the Knowledge-Action Gaps
<p><b> </b></p>
<p><strong>Article full
text</strong></p><p>
</p><p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-018-0744-7"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced digital features for this article</strong><br>
If you are an author of this publication and would like to provide additional
enhanced digital features for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as ‘peer reviewed’ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are
not limited to:<br>
• Slide decks<br>
• Videos and animations<br>
• Audio abstracts<br>
• Audio slides<u></u></p>
<p> </p